RecruitingEarly Phase 1NCT04592640
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Studying Calciphylaxis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Principal Investigator
- Ningning Wang, ProfessorThe First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital
- Intervention
- Human amniotic-derived mesenchymal stem cells(biological)
- Enrollment
- 9 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2018 – 2028
Study locations (1)
- The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China
Collaborators
Westlake University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04592640 on ClinicalTrials.govOther trials for Calciphylaxis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07511283Calciphylaxis in Patients With Chronic Kidney Disease - A Study of the Danish Calciphylaxis Research Initiative (DanCaRI)Odense University Hospital
- RECRUITINGNANCT04654000Rheopheresis as Adjuvant Treatment of CalciphylaxisUniversity Hospital, Lille
- RECRUITINGPHASE3NCT05018221Better Evidence and Translation for CalciphylaxisUniversity of Sydney
- RECRUITINGNCT03032835Partners Calciphylaxis BiobankMassachusetts General Hospital
- RECRUITINGNCT02280733A Real-World Registry of Chronic Wounds and UlcersU.S. Wound Registry